<DOC>
	<DOCNO>NCT00455936</DOCNO>
	<brief_summary>The investigator conduct randomize trial determine role Gefitinib monotherapy first-line setting adenocarcinoma patient history smoking , compare standard combination chemotherapy . This randomized , open label , parallel group , phase III study never-smokers advance metastatic adenocarcinoma lung . After stratification gender , performance status , disease stage , patient randomize one two treatment arm receive either gefitinib standard chemotherapy clinical objective disease progression , unacceptable toxicity patient 's refusal , whichever sooner . The chemotherapy administer nine cycle .</brief_summary>
	<brief_title>First-line Gefitinib Versus Chemotherapy Lung Adenocarcinoma Never Smoker</brief_title>
	<detailed_description>Gefitinib ( Iressa TM ) Arm - Gefitinib administration 250mg tablet daily every 3 week standard chemotherapy arm - gemcitabine ( 1,250mg/m2 30 minute day 1 8 3 week cycle ) plus cisplatin ( 80mg/m2 day 1 3 week cycle )</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis adenocarcinoma lung without BAC feature ; however , adenocarcinoma combine histology , small cell carcinoma squamous carcinoma , allow . 2 . Stage IIIB malignant pleural effusion/pleural seeding stage IV patient 3 . Age 1875 4 . Neversmoking define 100 cigarette lifetime 5 . ECOG performance status 02 6 . No prior invasive malignancy 5 year prior study entry except adequately treat cutaneous basal cell carcinoma uterine cervix situ cancer 7 . Serum creatinine ≤ 1.5 mg/dL , serum bilirubin ≤ 1.2 mg/dL ( 1 x UNL ) SGOT/SGPT ≤ 100 IU/L ( 2.5 x UNL ) 8 . Serum Hgb ≥ 10 gm/dl , platelet count ≥ 100,000/ul , total WBC count &gt; = 4,000/uL , absolute neutrophil count ≥ 1,500/ul 9 . Patients must sign informed consent indicate aware investigational nature study keep policy hospital . The approved consent form attach protocol 10 . The presence CNS metastases consider exclusion criterion , provide good control symptom corticosteroid 1 . Pregnancy breastfeeding ( woman childbearing potential ) . Women childbearing potential must practice acceptable method birth control prevent pregnancy . 2 . Major surgery biopsy within past two week . 3 . Known severe hypersensitivity Gefitinib excipients product 4 . Any evidence clinically active interstitial lung disease ( patient chronic , stable , radiographic change asymptomatic need exclude ) 5 . As judged investigator , evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) 6 . Evidence significant clinical disorder laboratory find make undesirable subject participate study 7 . Concomitant use phenytoin , carbamazepine , rifampicin , barbiturate , St John 's Wort 8 . Treatment nonapproved investigational drug within 30 day Day 1 study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>NSCLC</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Never smoker</keyword>
</DOC>